Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00626496 · ClinicalTrials.gov registry record
Family Study of Lymphoproliferative Disorders
A clinical trial of Multiple Myeloma and Lymphoma, Non-Hodgkin, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 3,000
- Enrollment target
- 1
- Study location
NCT00626496: Recruiting study of Multiple Myeloma and Lymphoma, Non-Hodgkin, sponsored by Mayo Clinic.
NCT00626496 is a study of Multiple Myeloma and Lymphoma, Non-Hodgkin that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 3,000 participants, above the 540-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (456% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00626496, a study of Multiple Myeloma and Lymphoma, Non-Hodgkin, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 3,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Blood and lymph node cancers can begin in either the lymphatic tissues (as in the case of lymphoma) or in the bone marrow (as with leukemia and myeloma), and they all are involved with the uncontrolled growth of white blood cells. There are many subtypes of these cancers, e.g., chronic lymphocytic leukemia and non-Hodgkin lymphoma. Since there is evidence that these cancers cluster in families, this study aims to understand how genetics and environmental exposures contribute to the development of these cancers.
Conditions Studied
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2004-04-01 |
| Est. Completion | 2029-12-31 |
What NCT00626496 shows while recruiting
NCT00626496 is an observational study that tracks outcomes without assigning an intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus, above the 540-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (456% higher).
The record links to 5 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 0 interventions.
NCT00626496 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00626496 about?
NCT00626496 is a clinical study titled "Family Study of Lymphoproliferative Disorders". Blood and lymph node cancers can begin in either the lymphatic tissues (as in the case of lymphoma) or in the bone marrow (as with leukemia and myeloma), and they all are involved with the uncontrolled growth of white blood cells. There are many subtypes of these cancers, e.g., chronic lymphocytic l...
What is the current status of trial NCT00626496?
This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2004-04-01. Estimated completion is 2029-12-31.
What conditions does trial NCT00626496 study?
This clinical trial studies the following conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Monoclonal B-Cell Lymphocytosis.
Who is sponsoring clinical trial NCT00626496?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00626496 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00626496's enrollment target sits among peer trials
3,000 10th of 438 higher than 429 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI